Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 211-242

  Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Myosin light chain 1; Oxidative stress; Peroxynitrite; Sarcomere; Tissue inhibitor of metalloproteinase (TIMP); Troponin I

Indexed keywords

DOXYCYCLINE; DOXYCYCLINE HYCLATE; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; MYOSIN LIGHT CHAIN; PHOSPHOPROTEIN; TETRACYCLINE; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TROPONIN I;

CYTOSKELETON; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART INJURY; HEART MUSCLE CELL; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SARCOMERE;

ANIMALS; GUINEA PIGS; HEART DISEASES; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MYOSIN LIGHT CHAINS; OXIDATIVE STRESS; RATS; SARCOMERES; TISSUE INHIBITOR OF METALLOPROTEINASES; TROPONIN I;

EID: 33847020733     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105230     Document Type: Review

References (113)

1. Gross J, Lapiere CM. 1962. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl. Acad. Sci. USA 48:1014-22
2. Chen J, Tung CH, Allport J, Chen S, Weissleder R, et al. 2005. Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 111:1800-5
3. Chapman RE, Spinale FG. 2004. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am. J. Physiol. Heart Circ. Physiol. 286:H1-10
4. Vanhoutte D, Schellings M, Pinto Y, Heymans S. 2006. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc. Res. 69:604-13
5. Hooper NM. 1994. Families of zinc metalloproteinases. FEBS Lett. 354:1-6
6. Galis Z, Sukhova GK, Lark M, Libby P. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:2493-500
7. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. 1993. Regulation of matrix metalloproteinas expression in human vein and microvascular endothelial cells. Biochem. J. 296:803-9
8. Tyagi SC, Matsubara L, Weber KT. 1993. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin. Biochem. 26:191-98
9. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG. 1999. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am. J. Physiol. Heart Circ. Physiol. 277:H777-87
10. Wang W, Schulze C, Suarez-Pinzon W, Dyck J, Sawicki G, et al. 2002. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-49
11. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP. 2001. Matrix metalloproteinase inhibition after myocardial infarction-a new approach to prevent heart failure. Circ. Res. 89:201-10
12. Dollery C, McEwan J, Henney AM. 1995. Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77:863-68
13. Spinale FG, Coker ML, Bond BR, Zellner JL. 2000. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 46:225-38
14. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski M, et al. 2000. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101:1833-39
15. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, et al. 2003. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc. Res. 57:426-33
16. Wang W, Sawicki G, Schulz R. 2002. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 53:165-74
17. Brown PD, Levy AT, Marguiles IM, Liotta LA, Stetler-Stevenson WG. 1990. Independent expression and cellular processing of Mr 72000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines Cancer Res. 50:6184-91
18. Cao J, Sato H, Takino T, Seiki M. 1995. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J. Biol. Chem. 270:801-5
19. O'Connor C, Fitzgerald MX. 1994. Matrix metalloproteinases and lung disease. Thorax 49:602-9
20. Stetler-Stevenson WG, Bersch N, Golde DW. 1992. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. 296:231-34
21. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, et al. 1995. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 92:2730-34
22. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, et al. 1994. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61-65
23. Birkedal-Hansen H. 1995. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:728-35
24. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution structure and function. Biochim. Biophys. Acta 1477:267-83
25. Williamson RS, Marston FA, Angal S, Koklitis P, Panico M, et al. 1990. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J. 268:267-74
26. Li YY, McTiernan CF, Feldman AM. 1999. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc. Res. 42:162-72
27. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. 1992. A new inhibitor of metalloproteinase from chicken: ChIMP-3. A third member of the TIMP family. J. Biol. Chem. 267:17321-26
28. Wu I, Moses MA. 1996. Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Gene 168:243-46
29. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, et al. 1996. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 271:30375-80
30. Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokka R, et al. 1997. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett. 401:213-17
31. Schulze C, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, et al. 2003. Imbalance between tissue inhibitor of metalloproteinases-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 107:2487-92
32. Tummalapalli CM, Heath BJ, Tyagi SC. 2001. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J. Cell Biochem. 80:512-21
33. Cox MJ, Hawkins UA, Hoit BD, Tyagi SC. 2004. Attenuation of oxidative stress and remodeling by cardiac inhibitor metalloproteinase protein transfer. Circulation 109:2123-28
34. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. 1992. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TEVIP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298:29-32
35. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, et al. 2003. A novel function for tissue inhibitor of metalloproteinase-3 (TIMP-3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9:407-15
36. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, et al. 2000. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J. Mol. Cell. Cardiol. 32:109-20
37. Fedak PWM, Smookler DS, Kassiri Z, Ohno N, Leco KJ, et al. 2004. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110:2401-9
38. English JL, Kassiri Z, Koskivirta I, Atkinson SJ, Di Grappa M, et al. 2006. Individual TIMP deficiencies differentially impact pro-MMP-2 activation. J. Biol. Chem. 281:10337-46
39. Peterson JT. 2004. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. 9:63-79
40. Peterson JT. 2006. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69:677-87
41. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina AP, et al. 1999. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17:768-74
42. Higashi S, Miyazaki K. 2003. Identification of a region of β-amyloid precursor protein essential for its gelatinase A inhibitory activity. J. Biol. Chem. 278:14020-28
43. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, et al. 1998. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv. Dent. Res. 12:12-26
44. Golub LM, Lee LM, Lehrer G, Nemiroff A, McNamara TF, et al. 1983. Minocycline reduces gingival collagenolytic activity during diabetes. J. Periodont. Res. 18:516-24
45. Trachtman H, Futterweit S, Garg P, Reddy K, Singhal PC. 1996. Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 218:704-8
46. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J. Clin. Invest. 98:2572-79
47. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. 2000. Peroxynitrite is a major contributor to cytokine induced myocardial contractile failure. Circ. Res. 88:241-47
48. Okamoto T, Akaike T, Nagano T, Miyajima S, Suga M, et al. 1997. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch. Biochem. Biophys. 342:261-74
49. Siwik DA, Pagano PJ, Colucci WS. 2001. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 280:C53-60
50. Okamoto T, Akaike T, Sawa T, Miyamoto T, van der Vliet A, et al. 2001. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J. Biol. Chem. 276:29596-602
51. Borges CR, Geddes T, Watson JT, Kuhn DM. 2002. Dopamine biosynthesis regulated by S-glutathionylation-potential mechanism of tyrosine hydroxylase inhibition during oxidative stress. J. Biol. Chem. 277:48295-302
52. Di Simplicio P, Franconi F, Frosali S, Di Giuseppe D. 2003. Thiolation and nitrosation of cysteines in biological fluid and cells. Amino Acids 25:323-39
53. Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, et al. 2002. Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. Proc. Natl. Acad. Sci. USA 99:3505-10
54. Huang KP, Huang FL. 2002. Glutathionylation of proteins by glutathione disulfide S-oxide. Biochem. Pharmacol. 64:1049-56
55. Owens MW, Milligan SA, Jourd'heuil D, Grisham MB. 1997. Effects of reactive metabolites of oxygen and nitrogen on gelatinase A activity. Am. J. Physiol. Lung Cell. Mol. Physiol. 273:L445-50
56. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, et al. 2002. S-nitrosylation of matrix metalloproteinases-signaling pathway to neuronal cell death. Science 297:1186-90
57. Viappiani S, Sawicki G, Crawford B, Leon H, Schulz R. 2006. Peroxynitrite modulates 72 kD matrix metalloproteinase-2 activity through S-nitrosylation of critical cysteines. J. Mol. Cell. Cardiol. 40:907 (Abstr.)
58. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PG. 1996. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett. 381:21-24
59. Chakraborti S, Mandal A, Das S, Chakraborti T. 2004. Inhibition of Na+/ Ca2+ exchanger by peroxynitrite in microsomes of pulmonary smooth muscle: role of matrix metalloproteinase-2. Biochim. Biophys. Acta 1671:70-78
60. Deleted in proof.
61. Bolli R, Marban E. 1999. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 79:609-34
62. Yasmin W, Strynadka KD, Schulz R. 1997. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc. Res. 33:422-32
63. Ferdinandy P, Schulz R. 2003. Nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 138:532-43
64. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, et al. 2002. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem. Biophys. Res. Commun. 296:937-41
65. Prasan A, McCarron HCK, White MY, McLennan SV, Tchen AS, et al. 2002. Duration of ischemia determines matrix metalloproteinase-2 activation in the reperfused rabbit heart. Proteomics 2:1204-10
66. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, et al. 2006. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am. J. Physiol. Heart Circ. Physiol. 291:H1838-46
67. Cursio R, Mari B, Louis K, Rostagno P, Saint-Paul MC, et al. 2002. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinase inhibitor. FASEB J. 16:93-95
68. Roach DM, Fitridge RA, Laws PE, Millard SH, Varelias A, et al. 2002. Upregulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury. Protection by the MMP inhibitor, doxycycline. Eur. J. Vasc. Endovasc. Surg. 23:260-69
69. Falk V, Soccal PM, Grunenfelder J, Hoyt G, Walther T, et al. 2002. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur. J. Cardiothorac. Surg. 22:53-58
70. Clark WM, Lessov N, Lauten JD, Hazel K. 1997. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J. Mol. Neurosci. 9:103-8
71. Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM. 2003. Doxycycline modulates smooth muscle cell growth, migration, and matrix re-modeling after arterial injury. Am. J. Pathol. 160:1089-95
72. Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, et al. 2001. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am. J. Physiol. Heart Circ. Physiol. 281:H987-94
73. Wang W, Viappiani S, Sawicka J, Schulz R. 2005. Inhibition of endogenous nitric oxide in the heart enhances matrix metalloproteinase-2 release. Br. J. Pharmacol. 145:43-49
74. Deleted in proof
75. Gao WD, Atar D, Liu Y, Perez NG, Murphy AM, et al. 1997. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. 80:393-99
76. McDonough JL, Arrell DK, Van Eyk JE. 1999. Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ. Res. 84:9-20
77. Murphy AM, Kogler H, Georgakopoulos D, McDonough JL, Kass DA, et al. 2000. Transgenic mouse model of stunned myocardium. Science 287:484-91
78. Galvez AS, Hahn HS, Odley A, Brunskill EW, Lynch RA, et al. 2004. Elucidation of an essential role for calpains in cardiac health. Circulation 110:III-197 (Abstr.)
79. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, et al. 2006. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc. Res. 69:688-96
80. Hein A, Scheffold T, Schaper J. 1995. Ischemia induces early changes to cytoskeletal and contractile proteins in diseased human myocardium. J. Thorac. Cardiovasc. Surg. 110:89-94
81. Matsumura Y, Saeki E, Inoue M, Hori M, Kamada T, et al. 1996. Inhomogenous disappearance of myofilament-related cytoskeletal proteins in stunned myocardium of guinea pig. Circ. Res. 79:447-54
82. Sung M, Schulz CG, Sawicka J, Sawicki G, Schulz R. 2004. Cytoskeletal protein alterations in myocardial ischemia/reperfusion injury: potential role of matrix metalloproteinases. J. Mol. Cell. Cardiol. 36:617 (Abstr.)
83. Van Eyk JE, Powers F, Law W, Lame C, Hodges RS, et al. 1998. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ. Res. 82:261-71
84. Tschuchida K, Kaneko K, Yamazaki R, Aihara H. 1986. Degradation of cardiac structural proteins induced by reperfusion in the infarcted myocardium. Res. Comm. Chem. Pathol. Pharmacol. 53:195-202
85. Yamada T, Matsumori A, Tamaki S, Sasayama S. 1998. Myosin light chain I grade: a simple marker for the severity and prognosis of patients with acute myocardial infarction. Am. Heart J. 135:329-34
86. Hansen MS, Stanton EB, Gawad Y, Packer M, Pitt B, et al. 2002. Canadian PROFILE investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am. J. Cardiol. 90:69-73
87. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, et al. 2005. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112:544-52
88. Sariahmetoglu M, Crawford BD, Leon H, Sawicka J, Li L, et al. 2006. Regulation of matrix metalloproteinase-2 activity by phosphorylation. J. Biol. Chem. In review
89. Murriel C, Mochly-Rosen D. 2003. Opposing roles of δ and εPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch. Biocbem. Biophys. 420:246-54
90. Sariahmetoglu M, Skrzypiec M, Leon H, Sawicka J, Holmes C, et al. 2004. Phosphorylation status of matrix metalloproteinase-2 and potential role in myocardial ischemia-reperfusion injury. Circulation 110:111-267 (Abstr.)
91. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, et al. 2004. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J. 18:690-92
92. Jackson DA, Cook PR. 1995. The structural basis of nuclear function. Int. Rev. Cytol. 162A:125-49
93. Martelli AM, Bareggi R, Bortul R, Grill V, Narducci P, et al. 1997. The nuclear matrix and apoptosis. Histochem. Cell Biol. 108:1-10
94. Georgi AB, Stukenberg PT, Kirschner MW. 2002. Timing of events in mitosis. Curr. Biol. 12:105-14
95. Owen CA, Campbell EJ. 1995. Neutrophil proteinases and matrix degradation. The cell biology of pericellular proteolysis. Sem. Cell Biol. 6:367-76
96. Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, et al. 2006. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am. J. Pathol. 169:1390-401
97. Pacher P, Schulz R, Liaudet L, Szabo C. 2005. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol. Sci. 26:302-10
98. Fernandez-Patron C, Radomski MW, Davidge ST. 1999. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85:906-11
99. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. 2000. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87:670-76
100. McQuibban GA, Gong JH, Tam EM, McCulloch CAG, Clark-Lewis I, et al. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289:1202-6
101. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, et al. 2003. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci. 6:1064-71
102. Kagawa N, Senbonmatsu T, Satoh K, Ichihara K, Yamagata N, et al. 2005. Tetracycline protects myocardium against ischemic injury. Front. Biosci. 10:608-19
103. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. 2003. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108:1487-92
104. Scarabelli TM, Stephanou A, Pasini E, Gitti G, Townsend P, et al. 2004. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to Smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and Smac/DIABLO. J. Am. Coll. Cardiol. 43:865-74
105. Yong VW, Wells J, Giuliani F, Casha S, Power C, et al. 2004. The promise of minocycline in neurology. Lancet Neurol. 3:744-51
106. Lalu MM, Gao CQ, Schulz R. 2003. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol. Cell. Biochem. 251:61-66
107. Lalu M, Csont T, Schulz R. 2004. Matrix metalloproteinase activities are altered in the heart and plasma during endotoxemia. Crit. Care Med. 32:1332-37
108. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. 1999. Antibiotics use and risk of subsequent first-time acute myocardial infarction. JAMA 281:427-31
109. Glenn L. 1999. Letter to Editor. JAMA 282:1997
110. Mayers I, Hurst T, Puttagunta L, Radomski A, Mycyk T et al. 2001. Cardiac surgery increases the activity of matrix metallloproteinases and nitric oxide synthase in human hearts. J. Thorac. Cardiovasc. Surg. 124:418-19
111. Breisblatt WM, Stein KL, Wolfe CJ, Follansbee WP, Capozzi J et al. 1990. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. J. Am. Coll. Cardiol. 15:1261-69
112. Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, et al. 2005. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur. Heart J. 26:27-35
113. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, et al. 2004. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol. 24:733-38